Unlike major depressive disorder, seasonal affective disorder usually lasts anywhere from a couple of weeks to a few months.

Neumora Therapeutics announced that its antidepressant candidate, navacaprant, did not meet the primary endpoint in a Phase 3 study for major depressive disorder.

Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...

Medically reviewed by Dakari Quimby, PhD Male postpartum depression describes when a new father experiences postpartum ...

Discover why psychiatrists are moving beyond single-treatment approaches and how combining therapies could be the key to ...

The National Institute of Mental Health defines depression, which is also known as clinical depression or major depressive ...

Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.

The Phase III KOASTAL-1 study with Neumora’s lead asset navacaprant failed to meet its primary and secondary endpoint.

Launched this year, Miami-based Hope Therapeutics is a developer of NRX-100, a ketamine drug used to treat suicidal ...

Neumora Therapeutics Inc.'s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals.

In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...

The study, first of the three late-stage trials, was testing the drug, navacaprant, in patients with major depressive ...